Montelukast Glenmark (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Glenmark, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Glenmark is used to manage conditions mediated by cysteinyl leukotrienes in the respiratory tract.

- Asthma: provides maintenance therapy to reduce bronchoconstriction and inflammation. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain in the head. - Upper respiratory tract infection: symptoms such as sore throat or runny nose. - Cough: occasional dry or productive cough. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Hepatotoxicity: elevated liver enzymes or jaundice (rare).

When prescribing Montelukast Glenmark, clinicians should consider several safety and handling points.

- Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: monitor infant for possible effects; decision based on clinical judgment. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant asthma exacerbation: ensure rescue inhaler is available. - Drug interactions: review patient’s medication list for known interactions. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Montelukast Glenmark can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: may reduce montelukast plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure, risk of side effects.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for neuropsychiatric effects. - Warfarin: possible alteration of anticoagulant effect. - Beta‑agonists: monitor for additive bronchodilation.